Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLWM4G)

• Drug Name: VX-15 Drug Info
• Synonyms: VX-15/2503; Plexin B1 antagonist (autoimmune disease/cancer), Vaccinex; Anti-CD100 MAb (autoimmune disease/cancer), Vaccinex;Anti-semaphorin 4D monoclonal antibody (autoimmune disease/cancer), Vaccinex

Indication

Disease Entry	ICD 11	Status	REF
Huntington disease	8A01.10	Phase 2	[1]
Multiple sclerosis	8A40	Phase 1	[2]
Non-small-cell lung cancer	2C25.Y	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DMLWM4G

Molecule-Related Drug Atlas

Drug(s) Targeting Neutral endopeptidase (MME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LCZ696	DMLFX7K	Heart failure	BD10-BD13	Approved	[6]
Candoxatril	DMHJCGV	Hypertension	BA00-BA04	Phase 3	[7]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[8]
SLV 306	DMCDON3	Acute decompensated heart failure	BD1Z	Phase 2	[9]
SLV-334	DMXCJKY	Brain injury	NA07.Z	Phase 2	[10]
Sampatrilat	DMXTOVE	Hypotension	BA20-BA21	Phase 2	[11]
SLV-338	DM7WKTM	Cardiovascular disease	BA00-BE2Z	Phase 1	[12]
GW-796406	DMQ46DN	Hypotension	BA20-BA21	Phase 1	[8]
Debio 0827	DMQIEFB	Chronic pain	MG30	Phase 1	[13]
CART-10 cells	DMQ4UJ6	Acute lymphoblastic leukaemia	2A85	Phase 1	[14]

Drug(s) Targeting Semaphorin-4D (SEMA4D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pepinemab	DM03GDJ	Squamous head and neck cell carcinom	2D60.0	Phase 1/2	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neutral endopeptidase (MME)	TT5TKPM	NEP_HUMAN	Inhibitor	[4]
Semaphorin-4D (SEMA4D)	TT5UT28	SEM4D_HUMAN	Not Available	[5]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01764737) Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Soli... Clin Cancer Res. 2016 Feb 15;22(4):827-36.
• [6] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [7] Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
• [8] Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
• [9] The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
• [10] Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
• [11] Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
• [12] Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
• [13] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [14] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [15] Clinical pipeline report, company report or official report of Vaccinex.